-
4 weeks ago | 
onlinelibrary.wiley.com | Adam Brufsky |Rickard Sandin |Stella Stergiopoulos |Connie Chen
1 Introduction Incidence rates of invasive breast cancer (BC) in the United States have increased since the mid-2000s, and BC is the second-leading cause of cancer-related death in women [1].
-
Aug 20, 2024 | 
cancernetwork.com | Adam Brufsky |Xianchen Liu |Benjamin Li |Lynn McRoy |Doris Makari |Rachel M. Layman | +2 more
BackgroundCardiovascular diseases (CVDs) can impact breast cancer treatment selection and clinical outcomes. A CDK4/6 inhibitor combined with endocrine therapy (ET) is now the standard of care as a first-line treatment for patients with hormone receptor–positive (HR+)/HER2-negative (HER2–) metastatic breast cancer. However, the effectiveness data of CDK4/6 inhibitors in patients with metastatic breast cancer and CVD are limited.
-
Jul 24, 2024 | 
onclive.com | Adam Brufsky
CommentaryVideoJuly 24, 2024Supplements and Featured PublicationsExamining the Novelty of Vaccine-Based Therapy in Metastatic Breast CancerAuthor(s):Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM. Adam M.
-
Jul 16, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
OpinionVideoJuly 16, 2024Author(s):Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion. Video content above is prompted by the following questions:Which emerging trials are promising in the treatment of HR+/HER2- locally advanced or metastatic breast cancer?
-
Jul 16, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast CancerMedical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.
-
Jul 9, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- mBCKey opinion leaders discuss clinical trials, including the EMERALD study, and targeted therapies for the treatment of metastatic estrogen receptor-positive (ER+) breast cancer in later lines of therapy.
-
Jul 9, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- breast cancer and led to its approval in the New England Journal of Medicine, emphasizing the improved progression-free survival observed in patients with PI3K/AKT/PTEN mutations.
-
Jul 2, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
Author(s):The panel examines how resistance mutations influence the effectiveness of subsequent treatment lines and delves into the process of selecting later-line therapies based on follow-up next-generation sequencing results. How does the identification of resistance mechanisms impact your clinical decision making? Do resistance mutations impact efficacy of later-line treatments? How does treatment resistance after 1L treatment create challenges in selecting 2L therapies?
-
Jul 2, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
Author(s):Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy. Please provide an overview of the mechanisms of resistance that can emerge following endocrine therapy and CDK4/6 inhibitors in HR+/HER2- breast cancer.
-
Jun 25, 2024 | 
onclive.com | Adam Brufsky |Erika P. Hamilton
OpinionVideoJune 25, 2024Author(s):Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions. Please discuss the role of biomarker testing in HR+/HER2- breast cancer.
